Norwood, MA (PRWEB) July 30, 2012
BioPharm Insight™, published by Infinata, covered the Alzheimer’s Association International Conference (AAIC) held in Vancouver earlier this month and found a significant focus on early intervention. In exclusive interviews, experts at the conference noted that disease modifying drugs must be administered even before symptoms appear in order for a demonstrable effect to be seen.
The future success of disease modifying candidates bapineuzumab and solanezumab was a topic of debate as some investigators interviewed by BioPharm Insight did not consider these drugs to be top contenders in the initiative to assess the hypoth¬esis of pre-symptomatic therapeutic intervention.
On the heels of the AAIC, Pfizer announced that bapineuzumab Phase III top-line results indicated the drug was not clinically effective in mild-to-moderate Alzheimer’s patients who are carriers of the ApoE4 gene. Top-line results from the bapineuzumab non-ApoE4 carrier trial as well as the solanezumab trial are eagerly awaited over the next few weeks.
Other highlights from the AAIC report include:
- Baxter’s Phase III GAP trial
- Bristol-Myers Squibb plans Phase III avagacestat trial
- Avanir’s AVP-923 in AD associated agitation
- Sales forecasts for Namenda, Aricept, Exelon, Bapineuzumab and Solanezumab
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.
About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.